Attention-Deficit/Hyperactivity Disorder (ADHD) is characterized by poor attention, impulsivity, hyperactivity and emotional-motivational dysregulation. Here, we will test if theta burst repetitive transcranial magnetic stimulation (rTMS) can reduce the symptoms of ADHD.
Background \& Rationale Attention-Deficit/Hyperactivity Disorder (ADHD) is characterized by poor attention, impulsivity, hyperactivity and emotional-motivational dysregulation. It has an estimated prevalence of 5% in children. Usually, ADHD in children is treated with stimulant medications, such as methylphenidate. However, these pharmacotherapy treatments have numerous unwanted side effects, including sleep disturbances, appetite changes, and emotional lability, and do not prove to be effective in every case. A promising and alternative option for reducing ADHD symptoms is non-invasive brain stimulation. Repetitive transcranial magnetic stimulation (rTMS) is a form of non-invasive brain stimulation which involves the application of a magnetic field to the skull to change the behaviour and function of underlying brain areas. In turn, rTMS leads to positive long-term changes in neurochemical activity, and while studies are limited, some have shown that rTMS can reduce ADHD symptoms in adolescents with ADHD. Methods Design: Open label TMS trial Primary Outcome: To examine the effect of active rTMS to the right prefrontal cortex on attention as measured by the TEACh-2 Outline: 1. Baseline Assessment (MRI Scan, assessment scales, neuropsychological testing) 2. rTMS intervention: 5 / week for 4 weeks. 3. Post-intervention Assessment (MRI Scan, assessment scales, neuropsychological testing).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Repetitive transcranial magnetic stimulation (rTMS)
Alberta Children's Hospital
Calgary, Alberta, Canada
RECRUITINGTEACH-2
Test of everyday attention in children - 2. Direct assessment of attention abilities in children.
Time frame: Baseline to week 5
SNAP-18
Parent reporting of ADHD symptom severity
Time frame: 5 weeks and 52 weeks.
PedsQL
Self reporting of quality of life
Time frame: Baseline to week 5
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.